Get notified when VFF files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRisk Profile Improvements
- Material Weakness (improved) — Material weaknesses in IT controls and journal entry review identified in 2024 were remediated by March 2025; controls now deemed effective after temporary pause during produce divestiture.
VFF exits U.S. produce, swings to profit on cannabis strength; new CBD ban threatens U.S. segment
Filed March 12, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 13, 2025 · ~2 min read
Key Changes
-
high
Sold most U.S. produce operations to Vanguard for $40M cash plus 37.9% equity stake in May 2025, retaining only Canadian Delta facility under supply contract. Transaction eliminates 44% of prior produce revenue from third-party grower commissions.
Business: Produce Transaction verify on EDGAR → -
high
November 2025 Appropriations Act will make most CBD products illegal starting November 2026, posing material threat to U.S. Cannabis segment (Balanced Health) unless Congress or regulators intervene.
Risk Factors: CBD illegality verify on EDGAR → -
high
Swung to $32.4M net income in 2025 from $35.9M loss in 2024, driven by record $49.9M adjusted EBITDA (up from $7.4M), gross margin expansion to 40%+, and $20M gain on produce sale. Initiated $10M share buyback.
MD&A: Profitability turnaround verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (TRV 10-Q) is open in full — no account needed.
Partner
Trade VFF commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 4, 2026 · How we verify